Spyre Therapeutics Announces Proposed Securities Offering

Spyre Therapeutics, a biotechnology firm focused on developing treatments for inflammatory bowel disease (IBD), has announced plans for a proposed securities offering. The final details of this offering will be disclosed in a prospectus supplement filed with the SEC. The offering is not yet available in jurisdictions where it is not registered or qualified.

Spyre Therapeutics aims to advance IBD treatment by integrating advanced antibody engineering, therapeutic combinations, and precision medicine. Their current pipeline includes investigational antibodies targeting α4β7, TL1A, and IL-23.

The press release includes forward-looking statements as per the U.S. Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, including market conditions, macroeconomic impacts, and geopolitical events that could influence the company's operations and the outcome of the proposed offering. Spyre Therapeutics acknowledges these risks and notes that actual results may differ from their forward-looking statements. The company commits to updating these statements only as legally required.